Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
PubMed Central, Lang, Thomas, et al
Hemoglobin A1C reductions become apparent at 8-12 weeks, with peak reductions typically occurring between 20-24 weeks of consistent treatment
Int J Mol Sci 26:2691
In a significant number of patients, MASLD coexists with other dysmetabolic traits, such as obesity and type 2 diabetes mellitus (T2DM), suggesting that MASLD is the hepatic manifestation of the metabolic syndrome (MetS), impacting approximately 30% of the global adult population [2, 3]
Causes of Inadequate Responsiveness to Therapy Pseudoresistance White-coat hypertension or office elevations Pseudohypertension in older patients Use of regular adult cuff on a very obese arm Nonadherence to therapy Volume overload Excess salt intake Progressive renal damage (nephrosclerosis) Fluid retention from reduction of blood pressure Inadequate diuretic therapy Drug-related causes Doses too low Wrong type of diuretic Inappropriate combinations Rapid inactivation (e.g., hydralazine) Drug actions and interactions Sympathomimetics Nasal decongestants Appetite suppressants Cocaine and other illicit drugs Caffeine Oral contraceptives Adrenal steroids Licorice (as may be found in chewing tobacco) Cyclosporine or tacrolimus Erythropoietin Antidepressants Nonsteroidal anti-inflammatory drugs Associated conditions Smoking Increasing obesity Sleep apnea Insulin resistance or hyperinsulinemia Ethanol intake of more than 1 oz (30 mL) per day Anxiety-induced hyperventilation or panic attacks Chronic pain Intense vasoconstriction (arteritis) Organic brain syndrome (e.g., memory deficit) Identifiable causes of hypertension Adapted from JNC-7 Express, National Heart, Lung, and Blood Institute
Dose-Pause and Discontinuation Patterns Trial protocols paused dosing for protocol-defined adverse events
